| 标题： | 十八反、十九畏理论的分类分层认识及其用于临床安全风险评估的药学专家共识 |
| title： | Classification and Stratification of the Eighteen Anti and Nineteen Fear Theories and their Consensus among Pharmaceutical Experts for Clinical Safety Risk Assessment |
| 版本： | 其他 |
| version： | Others |
| 分类： | 中医药指南 |
| classification： | Traditional Chinese Medicine guideline |
| 领域： | 综合 |
| field： | Comprehensive guideline |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 医疗机构的医师和药师，社会药店药师 |
| Guide users： | Physicians and pharmacists in medical institutions, pharmacists in social pharmacies |
| 证据分级方法： | 改良的德尔菲证据分级方法 |
| Evidence grading method： | Improved Delphi Evidence Grading Method |
| 制定单位： | 共识专家组 |
| Formulating unit： | Consensus Expert Group |
| 注册时间： | 2023-11-26 |
| Registration time： | |
| 注册编号： | PREPARE-2023CN958 |
| Registration number： | |
| 指南制订的目的： | 十八反、十九畏配伍禁忌理论是中医药基本理论内容之一，长期以来在学术界和临床界存在争议，有些观点认为是必须遵守的禁忌，有些观点认为不应作为禁忌而应视情况使用。本指南从药学角度出发，综合目前可以得到的各类资料和证据（基础实验，临床经验，古代文献等），对十八反、十九畏组合的分层分类认识及其用于临床安全风险评估的方法进行共识。 |
| Purpose of the guideline： | The theory of eighteen contraindications and nineteen contraindications for compatibility is one of the basic theories of traditional Chinese medicine. There has been controversy in the academic and clinical circles for a long time, with some views suggesting that it must be followed as a taboo, while others believe that it should not be used as a taboo and should be used according to the situation. This guideline takes a pharmaceutical perspective and integrates various available data and evidence (basic experiments, clinical experience, ancient literature, etc.) to reach a consensus on the hierarchical classification of the combination of eighteen antibodies and nineteen fears, as well as the methods used for clinical safety risk assessment. |
